Oncology Archive

A building with a stone facade displays a sign that reads
KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs
A building with a stone facade displays a sign that reads
Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release
A building with a stone facade displays a sign that reads
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
A building with a stone facade displays a sign that reads
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
A building with a stone facade displays a sign that reads
Rollover Study to Continue IMSA101 Treatments in Patients With Advanced Treatment-Refractory Malignancies Previously Enrolled in the Phase I/IIA Safety and Efficacy Study of IMSA101
A building with a stone facade displays a sign that reads
A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator’s Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)
A building with a stone facade displays a sign that reads
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
A building with a stone facade displays a sign that reads
IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator’s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)
A building with a stone facade displays a sign that reads
Cytokine Release Biospecimen Collection Protocol
A building with a stone facade displays a sign that reads
Trans-renal detection of pancreatic cancer